http://www.fpnotebook.com/
Thyroid Hormone ReplacementAka: Thyroid Replacement, Levothyroxine, Synthroid, Thyroxine Replacement, T4 Replacement
- Indications
- Hypothyroidism
- Preparations
- Generic levothyroxine bioequivalent to brand drugs
- See oral and intravenous dosing below
- Medication Interactions (Take 4 hours apart)
- Interfere with GI absorption (lower levels)
- Cholestyramine
- Colestipol
- Ferrous Sulfate
- Sucralfate
- Aluminum hydroxide antacids
- Calcium Supplementation
- Increase metabolism of Thyroxine (lowers levels)
- Phenytoin
- Carbamazepine (Tegretol)
- Rifampin
- Phenobarbital
- Warfarin (Coumadin)
- Oral Hypoglycemic agents
- Medications interfere with T4 production (lower levels)
- Lithium
- Amiodarone
- Medications containing iodine
- Medications increasing protein binding (lowers levels)
- Pregnancy (high Estrogenic state)
- Oral Contraceptive
- Estrogen Replacement
- Medications decreasing protein binding (raises levels)
- Furosemide (Lasix)
- Mefenamic acid (Ponstel)
- Salicylates
- Androgens
- Decreased Serum Proteins with aging
- Nephrotic Syndrome
- Cirrhosis
- Protein-losing enteropathy
- Dosing (lower dosing in Subclinical Hypothyroidism)
- Anticipated total dose (50 to 200 ug/day)
- Children: up to 4 ug/kg/day (full replacement)
- Adults: 1.7 ug/kg/day
- Elderly: 1 ug/kg/day
- Younger persons (no comorbid conditions)
- Usual starting dose: 75 to 100 ug qd
- Options for initiating dosing
- Option 1
- Start at 75 to 100 ug qd
- Option 2
- Start at 0.8 ug/kg/day (50% of anticipated dose)
- Increase to 1.7 ug/kg/day at 2 weeks
- Age over 50 years or history of heart disease
- Start at 12.5 to 25 ug qd
- Increase by 25 to 50 ug increments every 4-6 weeks
- Follow Thyroid Stimulating Hormone (TSH) closely
- Special Circumstances
- Intravenous dosing
- Indicated if unable to take oral dose for >7 days
- Parenteral dose is 70-80% of usual oral dose
- Adding T3 to T4 may improve neuropsychiatric symptoms
- See Liothyronine (Cytomel)
- Recent study suggests no benefit
- Clyde (2003) JAMA 290:2952
- Adverse Effects: Excessive Thyroid Replacement
- Cardiac hypertrophy
- Increased Intraventricular septum thickness
- Increased Left Ventricular posterior wall thickness
- Increased End Diastolic Dimension
- Increased Left Ventricular Mass Index
- Decreased Exercise Tolerance
- Decreased VO2 Max
- Decreased Anaerobic threshold
- Monitoring
- Protocols for monitoring
- Monitoring every 6 to 8 weeks
- TSH not yet stabilized after initiation
- Recent change in Thyroid replacement dosing
- Monitoring annually
- Age over 50 years
- Weight change
- Monitoring less frequently than annually
- Age under 50 years with weight stable
- No comorbid condition
- Specific Testing
- Thyroid Stimulating Hormone
- Lags levothyroxine dose change by 6 weeks
- Target adjusting TSH to the normal mid-range
- Thyroxine (T4)
- Lags levothyroxine dose change by 1-2 weeks
- References
- Svec (2001) CMEA Medicine Lecture, San Diego
- Dong (1997) JAMA 277:1205
- Hueston (2001) Am Fam Physician 64:1717
- Mercuro (2000) J Clin Endocrinol Metab 85:159
- Singer (1995) JAMA 273:808
- Surks (1995) N Engl J Med 333:1688
|
|---|
| Concepts | Amino Acid, Peptide, or Protein (T116)
, Pharmacologic Substance (T121)
|
| English | Abbot Brand of Levothyroxine Sodium, Synthroid |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree